BPC-157: the version I wish someone had shown me in week 1
BPC-157: the version I wish someone had shown me in week 1. Numbers below. Ask me the boring questions, they are the useful ones. Kept a reconstituted vial too long out of curiosity and learned something about solution stability I would rather have read. Why identity, not purity, is the test to buy here. This is a…
The published literature is overwhelmingly preclinical, largely in rodent models. Translating a rodent result into a human expectation is not a small step, and almost every confident claim here takes it silently.
Small fix — fifteen residues, not seventeen. The sequence is public and easy to check.
identity testing matters more here than purity does
Agreed. Identity is the question here. A short peptide can be synthesised by almost anyone and the sequence is what you are actually buying.
identity, quantity, stability — three separate questions
identity testing matters more here than purity does
This is the point that should be at the top of every thread here. Identity first.
Small fix — fifteen residues, not seventeen.
Disagreeing with this line: that paper is in a rodent model and it is being quoted as a human result.
stability in solution is the practical question nobody asks
short peptides are cheap, which cuts both ways
read the actual papers, they are more modest than the summaries
a fifteen-residue peptide is easy to make and easy to make badly
Research-use-only material is not approved for human use. In this board that is not a formality — it is the reason the clinical evidence base is as thin as it is.